High Dose Ascorbic Acid Treatment of CMT1A

This study has been completed.
Sponsor:
Collaborators:
Muscular Dystrophy Association
Charcot-Marie-Tooth Association
Information provided by (Responsible Party):
Michael E. Shy, MD, Wayne State University
ClinicalTrials.gov Identifier:
NCT00484510
First received: June 8, 2007
Last updated: March 4, 2013
Last verified: March 2013
  Purpose

This study will look at the impact of ascorbic acid (Vitamin C) on the progression of disease in people with CMT1A as compared to volunteers receiving a placebo. This study will assess whether is it futile to proceed with a larger, longer-term, placebo-controlled study.


Condition Intervention Phase
Charcot-Marie-Tooth Disease, Type Ia
Drug: Ascorbic acid (Vitamin C)
Drug: placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A.

Resource links provided by NLM:


Further study details as provided by Wayne State University:

Primary Outcome Measures:
  • Mean change in the CMT Neuropathy Scale following high dose ascorbic acid ingestion, assessed at baseline and every 6 months throughout the trial. [ Time Frame: 25 months per subject from baseline to completion. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of PMP22 mRNA levels of myelinated peripheral nerve fibers. [ Time Frame: Baseline and Month 24. ] [ Designated as safety issue: No ]

Enrollment: 110
Study Start Date: April 2007
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ascorbic Acid Drug: Ascorbic acid (Vitamin C)
Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
Placebo Comparator: Placebo Drug: placebo
Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.

Detailed Description:

Charcot Marie Tooth disease (CMT), or inherited peripheral neuropathies, are among the most frequent heritable disorders, affecting approximately 1 in 2500 people. The most frequent genetic form of CMT is CMT1A. CMT1A is caused by a 1.4 Mb duplication within chromosome 17p11.2 in the region containing the PMP22 gene. Most subjects with CMT1A have a "typical" phenotype characterized by onset in childhood or early adulthood, distal weakness, sensory loss, foot deformities and absent reflexes. How increased expression of PMP22 causes these disabilities is unknown but is currently being investigated in both animal and tissue culture systems. In this study, researchers will evaluate whether ascorbic acid (Vitamin C), administered orally, slows clinical progression of CMT1A and affects the PMP22 mRNA levels of myelinated peripheral nerve fibers obtained from biopsies of glabrous skin.

  Eligibility

Ages Eligible for Study:   13 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject has CMT1A, defined by the duplication on chromosome 17p11.2 performed by either Pulse Field Gel Electrophoresis or Fluorescence In Situ Hybridization (FISH) by a CLIA certified laboratory, OR the subject has a first or second degree relative with a documented duplication performed by the above methods AND the subject has uniform motor conduction slowing of the median or ulnar nerve between 16 and 30 m/s.
  • The subject is between 13 and 70 years of age.
  • The subject, if 18 years or older, has signed the Informed Consent Form and agrees to follow the stipulations of the protocol.
  • If the subject is less than 18, his or her parents or guardians have signed the Informed Consent Form and agree to follow the stipulations of the protocol. The subject has also signed a written assent form.

Exclusion Criteria:

  • A known neuropathy from another source (For example, diabetes, drug induced, alcohol, etc.)
  • The subject has ever received Vincristine.
  • The subject has a known allergy to ascorbic acid.
  • The subject has ever had kidney stones.
  • The subject has a known history of G6PD deficit.
  • The subject has a history of hemochromatosis.
  • The subject suffers from a serious illness or medical condition that is not stabilized or that could require hospitalization.
  • The subject has a high ascorbic acid level at screening.
  • The subject is pregnant or nursing.
  • The subject, in the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason.
  • The subject participates to another clinical trial or is still within a washout period of a previous clinical trial.
  • The subject is taking neurotoxic medications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00484510

Locations
United States, Maryland
Johns Hopkins University, Dept of Neurology
Baltimore, Maryland, United States, 21287
United States, Michigan
Wayne State University, Dept of Neurology
Detroit, Michigan, United States, 48201
United States, New York
University of Rochester Medical Center, Dept of Neurology
Rochester, New York, United States, 14642
Sponsors and Collaborators
Wayne State University
Muscular Dystrophy Association
Charcot-Marie-Tooth Association
Investigators
Principal Investigator: Richard A Lewis, MD Wayne State University, Dept. of Neurology
  More Information

Additional Information:
No publications provided by Wayne State University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael E. Shy, MD, Professor, Wayne State University
ClinicalTrials.gov Identifier: NCT00484510     History of Changes
Other Study ID Numbers: HIC074406MP2F, MDA4193
Study First Received: June 8, 2007
Last Updated: March 4, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Wayne State University:
Ascorbic Acid
Vitamin C
Charcot Marie Tooth
CMT
CMT1a

Additional relevant MeSH terms:
Charcot-Marie-Tooth Disease
Nerve Compression Syndromes
Tooth Diseases
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Genetic Diseases, Inborn
Stomatognathic Diseases
Hereditary Sensory and Motor Neuropathy
Nervous System Malformations
Polyneuropathies
Congenital Abnormalities
Ascorbic Acid
Vitamins
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on July 29, 2014